Bluefin Capital Management’s Takeda Pharmaceutical TAK Stock Holding History

Bluefin Capital Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-25,900	Closed	-$3K	–	864
2021 Q1	$3K	Buy	+25,900	New	+$466K	﹤0.01%	744
2019 Q2	–	Sell	-955,300	Closed	-$194K	–	469
2019 Q1	$194K	Buy	+955,300	New	+$19.2M	0.03%	215

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Bluefin Capital Management's TAK Position: Q2 2026 in Review

Bluefin Capital Management sold out of Takeda Pharmaceutical (TAK) in Q2 2026, closing a stake of 10,900 shares — an estimated $202K sold.

Bluefin Capital Management first reported a position in TAK in Q1 2019 and held it in 4 quarters. The position peaked at $24.5M in Q1 2019. 378 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Bluefin Capital Management reported no remaining Takeda Pharmaceutical position as of Q2 2026 after selling out during the quarter.
Bluefin Capital Management sold 10,900 Takeda Pharmaceutical shares in Q2 2026, an estimated $202K.
Bluefin Capital Management first reported a position in Takeda Pharmaceutical in Q1 2019 and held it in 4 quarters.
Bluefin Capital Management's Takeda Pharmaceutical position peaked at $24.5M in Q1 2019.
378 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Bluefin Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.